Dr. Keith Dawkins and Dr. Takahiro Uchida to join the Company
NATICK, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Boston Scientific today announced that Keith Dawkins, M.D., and Takahiro Uchida, M.D., will be joining the Company's Clinical Sciences organization.
Dr. Dawkins will serve as Senior Vice President and Associate Chief Medical Officer, sitting on both the Clinical Leadership team and the Company's Operating Committee. He is an internationally known senior interventional cardiologist at Southampton University Hospital in England, and a former President of the British Cardiovascular Society. He trained in medicine at London University (Guy's Hospital), and in cardiology at the Brompton Hospital (London), John Radcliffe Hospital (Oxford), and Stanford University Medical Center. He has served as an advisor to the Department of Health in the United Kingdom, and he has worked closely with a number of regulatory agencies there, including the Medicines and Healthcare Products Regulatory Agency (MHRA) and the National Institute for Clinical Excellence (NICE).
He will be responsible for leading the medical input process for the Company's Interventional Cardiology, Peripheral Intervention and Neurovascular businesses. He will also participate in the formulation and execution of technology strategies for both internal research and development, as well as business development activities. In addition, he will oversee development and dissemination of scientifically based education materials to inform customers and regulators.
"We are delighted to have Dr. Dawkins joining us," said Donald S. Baim, M.D., Boston Scientific's Chief Medical and Scientific Officer. "He is a well-published scientific contributor who has been actively involved in the development of the TAXUS(R) Stent System. He is also a respected medical lecturer who is universally recognized for his keen insights into a broad variety of cardiology and cardiology device-related issues. The addition of Dr. Dawkins will greatly enhance the capabilities of the Clinical Sciences organization at Boston Scientific."
Dr. Dawkins will join the Company in January.
Dr. Takahiro Uchida, who will serve as a Director in Clinical Research and as Medical Director, International, is another key addition to the Clinical Sciences organization. He is a skilled interventional cardiologist who received his Medical Degree from Fukushima Medical University, followed by an M.S. in Epidemiology from the Harvard School of Public Health, and a Doctor of Philosophy in Medicine from Tokyo Women's Medical University. After training with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), Dr. Uchida became a research fellow in the Division of Clinical Biometrics at the Brigham and Women's Hospital and the Harvard Clinical Research Institute. Most recently, Dr. Uchida has served as a Medical Officer in the Interventional Cardiovascular Device Branch of the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration.
He will be responsible for providing high-level medical input on the design, regulatory strategy and conduct of a broad range of international trials concentrated in the cardiovascular area, while also providing a strong communication link to the key regulatory bodies and customer base worldwide.
"Dr. Uchida will play an important role on our global Clinical Sciences team," said Dr. Baim. "He is well qualified for his important new role by virtue of his training as an interventional cardiologist, uniquely augmented by his experience with clinical trials from both the biostatistical trial conduct and regulatory perspectives, through his service with the Japanese and U.S. regulatory agencies."
Dr. Uchida will join the Company in December.
"The addition of these two highly capable individuals significantly strengthens Boston Scientific's Clinical Sciences' capabilities, and further enhances our ability to serve as the 'voice of the patient' by providing the highest-level expert clinical input throughout the product life cycle of our current and future medical devices," added Dr. Baim. "Combined with the talents of nearly 400 other professionals within our group, the unique skills and contributions of Dr. Dawkins and Dr. Uchida will be invaluable in helping us maintain and expand Boston Scientific's worldwide leadership in the treatment of cardiovascular disease and the broad range of other life- threatening and disabling diseases."
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical science, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
CONTACT: Paul Donovan
Boston Scientific Corporation
Boston Scientific Corporation
|SOURCE Boston Scientific Corporation|
Copyright©2007 PR Newswire.
All rights reserved